89bio Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" 89bio stock.
View analyst ratings for 89bio or view top-rated stocks.

Wall Street analysts have given 89bio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but 89bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

89bio is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for 89bio.

89bio, Inc. (NASDAQ:ETNB) released its earnings results on Tuesday, May, 11th. The company reported ($0.74) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.70) by $0.04.
View 89bio's earnings history.

89bio's stock was trading at $33.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ETNB stock has decreased by 43.8% and is now trading at $18.86.
View which stocks have been most impacted by COVID-19.

8 brokers have issued 12 month price targets for 89bio's stock. Their forecasts range from $35.00 to $95.00. On average, they anticipate 89bio's stock price to reach $58.13 in the next year. This suggests a possible upside of 208.2% from the stock's current price.
View analysts' price targets for 89bio or view top-rated stocks among Wall Street analysts.

Some companies that are related to 89bio include uniQure (QURE), Indivior (INVVY), Kura Oncology (KURA), PMV Pharmaceuticals (PMVP), PureTech Health (PRTC), COMPASS Pathways (CMPS), Avid Bioservices (CDMO), Generation Bio (GBIO), Kronos Bio (KRON), Stoke Therapeutics (STOK), Design Therapeutics (DSGN), Arcutis Biotherapeutics (ARQT), Innoviva (INVA), Edgewise Therapeutics (EWTX) and MacroGenics (MGNX).
View all of ETNB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), Honeywell International (HON), Raytheon Technologies (RTX), Alibaba Group (BABA), The Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO).

(ETNB) raised $70 million in an initial public offering (IPO) on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

89bio trades on the NASDAQ under the ticker symbol "ETNB."

89bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.50%), Acuta Capital Partners LLC (1.96%), Morgan Stanley (1.69%), JPMorgan Chase & Co. (1.08%), Pekin Hardy Strauss Inc. (0.91%) and Geode Capital Management LLC (0.71%). Company insiders that own 89bio stock include Gregory Grunberg, Longitude Capital Partners Iii, Orbimed Advisors Llc, Ra Capital Management, LP, Ram Waisbourd and Ryan Martins.
View institutional ownership trends for 89bio.

ETNB stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Acuta Capital Partners LLC, Phoenix Holdings Ltd., Alyeska Investment Group L.P., JPMorgan Chase & Co., Squarepoint Ops LLC, Northern Trust Corp, and Millennium Management LLC. Company insiders that have sold 89bio company stock in the last year include Gregory Grunberg, Orbimed Advisors Llc, Ram Waisbourd, and Ryan Martins.
View insider buying and selling activity for 89bio or view top insider-selling stocks.

ETNB stock was purchased by a variety of institutional investors in the last quarter, including Pekin Hardy Strauss Inc., Verition Fund Management LLC, BlackRock Inc., Geode Capital Management LLC, Goldman Sachs Group Inc., Cubist Systematic Strategies LLC, Bourgeon Capital Management LLC, and Chicago Partners Investment Group LLC. Company insiders that have bought 89bio stock in the last two years include Longitude Capital Partners Iii, Orbimed Advisors Llc, and Ra Capital Management, LP.
View insider buying and selling activity for 89bio or or view top insider-buying stocks.

Shares of ETNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ETNB stock can currently be purchased for approximately $18.86.

89bio has a market capitalization of $378.33 million. The company earns $-49,500,000.00 in net income (profit) each year or ($3.08) on an earnings per share basis.

89bio employs 26 workers across the globe.

The official website for 89bio is www.89bio.com.

89bio is headquartered at 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104.

89bio's mailing address is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. The company can be reached via phone at 415-500-4614 or via email at [email protected]